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Objective: Little is known about willingness among people living with HIV (PLHIV) to participate in HIV cure
research in the Netherlands. We compared results of a cross-sectional questionnaire assessing hypothetical will-
ingness to actual willingness among PLHIV to take part in a clinical HIV cure trial.
Methods: Between March and June 2018, PLHIV visiting the outpatient clinic of a university hospital in the
Netherlands were asked to complete a questionnaire about HIV cure research. Results were compared to the
number of PLHIV willing to take part in an actual HIV cure study at the same center during an overlapping time
period.
Results: In total, 165 participants, predominantly male (80%) from Western European countries (61%) completed
the questionnaire. The majority would participate in cure research (n ¼ 111, 67%). Separately, actual willingness
among PLHIV to participate in an HIV cure study was addressed in 312 cases. Apart from gender (96% male),
baseline characteristics were comparable. Less than half expressed actual willingness to participate in the study (n
¼ 135, 43%).
Conclusions: Hypothetical willingness to participate in cure-related research was high among PLHIV who
completed the questionnaire. Actual willingness among eligible PLHIV to take part in an HIV cure study was much
lower. Our findings show that questionnaires may overestimate willingness to participate in HIV cure trials and
indicate that reasons for refusal in actual research should be further explored.Introduction
Currently, little is known about willingness among people living with
HIV (PLHIV) to participate in cure-related research in the Netherlands [1].
Since most of the studies in the field of HIV cure are either preclinical or
early phase clinical trials [2], PLHIV who participate in HIV cure research
cannot expect an immediate clinical benefit at this stage. Therefore,
assessing the view of PLHIV is important, and indeedwas defined as one of
the key recommendations of the International AIDS Society global scien-
tific strategy [3]. Such information is crucial to determine acceptability of
HIV cure research and trial participation, and helps guide (future) HIV cure
research [4]. Previous studies showed that PLHIV consider participation in
HIV cure research mainly for altruistic reasons [5–8]. Some participants
indicated that they would need more information and education about the
potential risks before taking part in HIV research [5, 8]. Furthermore, threel Microbiology and Infectious D
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Netherlands, United Kingdom and USA showed that HIV cure research is
highly acceptable, and that many PLHIV who are willing to participate in
HIV cure research would accept risks, including antiretroviral therapy
(ART) interruption [1, 9, 10]. However, since online questionnaires often
rely on self-selection, the results should be interpreted with caution. Here,
we compare the results from a questionnaire about hypothetical willing-
ness to take part in HIV cure research to actual willingness to participate in
an HIV cure study among PLHIV visiting the same outpatient clinic in the
Netherlands during an overlapping period of time.
Methods
We conducted two separate studies. First, a quantitative, cross-
sectional questionnaire in the Dutch and English language containingiseases, Erasmus University Medical Center, Wytemaweg 2, Rotterdam, the
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towards HIV cure research [6, 9, 10]. It was adjusted with the help of
healthcare professionals from the Erasmus University Medical Center
(MC), Rotterdam who are involved in research questionnaires as well as
HIV care and HIV cure research (AV, CR, HP, SB) (appendix). After
approval of the Medical Ethics Review Committee, PLHIV visiting the
HIV outpatient clinic of the Erasmus MC between March and June 2018
were asked to fill out the questionnaire. Inclusion criteria for the study
were age 18 years and understanding of the spoken Dutch or English
language. After providing written informed consent, participants
completed the questionnaire in the presence of the investigator. One
question could be answered by “yes”, “no”, or “maybe”. The others
included a 5-point Likert scale ranging from 1 ¼ “very important” or
“very likely” to 5 ¼ “totally not important” or “totally not likely”. The
investigator, a medical student, was present when participants filled out
the questionnaire, and provided an explanation if a question was not
understood or if the participant was illiterate (n ¼ 4). All demographic
characteristics of the PLHIV who completed the questionnaire (n ¼ 165)
were retrieved from electronic patient records.
Separately, PLHIV visiting the outpatient clinic of the Erasmus MC
between January and December 2018 were screened for eligibility to take
part in a randomized controlled clinical trial involving latency reversing
agents (LUNA).[11] Eligible PLHIV were informed by their treating
physician about a trial involving two weeks of study medication and ten
study visits with phlebotomies. PLHIVwere informed that their ARTwould
not be interrupted and that participation would not lead to cure. If PLHIV
expressed willingness to participate they were referred to the HIV clinical
trial unit for additional screening. Demographic characteristics were
retrieved from Stichting HIV Monitoring Netherlands [12] for all the 312
eligible PLHIV with whom participation in the HIV cure study was
discussed.
Results
Hypothetical willingness to participate in HIV cure research
A total of 165 PLHIV completed the questionnaire, 80% (n ¼ 132)
were men with a median age of 50 years (interquartile range (IQR):
41–58). The majority (n ¼ 100, 61%) were born in Western Europe,
followed by the Caribbean (n¼ 27, 16%) and Sub Saharan Africa (n¼ 25,
15%). The main mode of transmission was male to male sexual contact (n
¼ 93, 56%) or heterosexual transmission (n ¼ 66, 40%). Most partici-
pants were currently on ART (n ¼ 162, 98%) with an undetectable
plasma viral load of <20 copies/mL (n ¼ 148, 90%). These patient
characteristics are representative for the general outpatient at the Eras-
mus MC (data not shown).Fig. 1. Selected number of questions from the questionnaire (appendix). 1A. Importa
potential advantages of HIV cure research. Bars in the chart columns are based on p
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Almost all participants (n ¼ 163, 99%) indicated that HIV cure
research was “very important”. Over two-thirds (n ¼ 111, 67%)
responded “yes” to the question whether they would participate in HIV
cure research for altruistic reasons, while 7% (n ¼ 11) answered
“maybe”. Fig. 1A shows the perceived importance of six potential dis-
advantages or risks of HIV cure research. A higher HIV transmission risk,
having to interrupt ART, and viral rebound were considered ‘very
important’ by 82% (n ¼ 136), 58% (n ¼ 96) and 68% (n ¼ 112)
respectively. Responses to the questions regarding undergoing extra
invasive procedures such as phlebotomies and additional hospital visits
were more diverse; 18% (n ¼ 30) and 22% (n ¼ 36) stated that these
disadvantages were “very important”, while respectively 45% (n ¼ 74)
and 38% (n ¼ 63) answered “totally not important” to these questions.
The most important potential advantages according to the majority of the
participants (n ¼ 152, 92%) were not being able to transmit HIV after a
cure and, depending on the cure approach, not being able to become re-
infected with HIV after cure. Furthermore, 69% (n ¼ 114) answered that
losing HIV stigma was “very important”, while 9% (n ¼ 15) indicated
that this was “totally not important” (Fig. 1B). Having fewer HIV-related
health problems and contributing to scientific knowledge was “very
important” to respectively 74% (n ¼ 122) and 84% (n ¼ 138).Actual willingness to participate in an HIV cure trial
During 2018, 2036 PLHIV visiting the outpatient clinic of the Erasmus
MC were screened for eligibility for a clinical HIV cure study (11). In
total, 594 PLHIV were eligible and physicians treating 312 candidates
addressed participation during the consultation. Since females in the
reproductive age were excluded from the trial, most of the 312 eligible
PLHIV were male (n ¼ 299, 96%). The majority (n ¼ 235, 75%) origi-
nated from Western Europe, followed by Sub Saharan Africa or the
Caribbean (n ¼ 35, 11%), and 9% (n ¼ 29) from Eastern Europe or Asia.
Median age was 50 years (IQR: 42–58). Main mode of HIV transmission
was male to male sexual contact (n ¼ 225, 72%).
Of the 312 cases in which participation was addressed, 43% (n¼ 135)
indicated willingness while 57% (n ¼ 177) refused, either at their own
discretion (n ¼ 131, 74%) or because the treating physician judged that
they were not suited for inclusion at that moment (n ¼ 46, 26%). PLHIV
who refused most commonly gave no reason (n¼ 53, 40%) or considered
participation not logistically feasible (n¼ 50, 38%). Others indicated not
to be interested (n ¼ 16, 12%) or gave different reasons (n ¼ 12, 9%).
Discussion
For this questionnaire, PLHIV attending a large HIV outpatient clinic
in Western Europe were approached without preselection. Of the PLHIVnce of potential disadvantages and risks of HIV cure research. 1B. Importance of
ercentages (not shown).
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HIV cure studies in a hypothetical scenario. Participation rates predicted
by the questionnaires are in line with previous online surveys that indi-
cate that at least 50% of the participants would participate in HIV cure
studies without personal benefits (9, 10). Separately, but during an
overlapping period of time at the same medical center, a larger, pre-
screened number of PLHIV was approached to take part in an HIV cure
study. Here, actual willingness among PLHIV to take part in HIV cure
research was considerably lower. A reason for refusal to participate that
was commonly given was that participation was logistically unfeasible.
These findings might partly reflect the need expressed by PLHIV for more
information and education about the potential risks and logistical im-
plications of participating in HIV cure research (5, 8). However, given the
personal, behavioral, ethical and social implications of participating in
HIV cure research, the reasons for refusal are likely to extend beyond
logistic impracticalities. To comprehend such motives, and why refusal
rates are higher when faced with the actual opportunity to participate in
HIV cure research, it is important to understand of the meaning of HIV
cure to PLHIV, and what they deem acceptable risks (3, 4). It would also
be interesting to further explore the reasons why treating physicians
judged some eligible PLHIV as unsuitable for inclusion in a clinical HIV
cure study.
To our knowledge, this is the first time a questionnaire assessing
hypothetical willingness to participate in HIV cure research is compared
to the actual willingness of PLHIV to take part in an HIV cure study
during an overlapping period of time at the same medical center. In this
case, the questionnaire overestimated hypothetical willingness when
compared to actual willingness to take part in a specific HIV cure study. A
possible explanation for this observation is that logistical feasibility is a
less influential factor in a hypothetical context. However, the reasons
why PLHIV decline to participate in HIV cure research likely extend
beyond logistic impracticalities.
Limitations
The cross-sectional questionnaire has a number of potential limita-
tions. There is no missing data since the investigator was present while
participants filled out the questionnaire. However, this might have
introduced some social desirability bias. Moreover, participants who did
not understand the Dutch or English language could not be included, and
permission to take part in the questionnaire was asked by the treating
physician, possibly introducing selection or referral bias. With regard to
the HIV cure trial, PLHIV were pre-screened for eligibility while PLHIV
approached to fill out the questionnaire were not. Comparison between
the two distinct groups should be made with caution, and further studies
are needed to explore these findings. Permission to take part in the HIV
cure study was also asked by the treating physician and could also have
led to referral bias. To avoid such biases in the future, assistance of an
HIV specialized nurse could prove helpful in ascertaining that all PLHIV
who visit the outpatient clinic are systematically asked to take part in a
study. Finally, the questionnaire assessed willingness to take part in HIV
cure research in general whereas the HIV cure study that PLHIV were
asked to take part in was a randomized controlled trial involving latency
reversing agents. Another type of HIV cure study may have resulted in a
different level of willingness to participate.
Conclusion
In conclusion, while participation in cure studies is altruistic and may
involve individual health-related risks, our findings indicate a high level3
of willingness to participate in hypothetical HIV cure research among
PLHIV. Actual willingness among a larger pre-screened population to
take part in an HIV cure study was much lower. These findings indicate
that questionnaires may overestimate hypothetical willingness to
participate in HIV cure studies. However, further studies comparing
hypothetical willingness to actual willingness to take part in different
types HIV cure trials are needed. Although information about logistic
implications is key, reasons for refusal to take part in HIV cure research
are likely to extend beyond impracticalities. Therefore, understanding
how PLHIV perceive HIV cure and clear communication about the im-
plications of participation in HIV cure research is vital.
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